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INTRODUCTION: 
Man's incessant quest for knowledge has led to, a stupendously large number 
of discoveries and inventions over the centuries. One of his most fascinating 
: )d challenging but historically more recent ef\deavours has been towards 
-::t~e development of new chemical entities as drugs, which has had a tremend-
.; ,: 
o~ impact on society. The availability of drugs has resulted in a drastic 1,-
r¥?uction of morbidUy and mortality and to an abundant improvement in \- .. , 
t~ quality of human life. These exercises havE' led to a profound increase 
,ft? - our basic knowledge of living systems and Qugmented our awareness of 
_-~ci likely caUges of their distortions and disruptions. at an increaSingly more 
ft1it:Jamental level. Furtller, a vigorous and e,,€r-erpanding drug indu~try is 
. -
contributing to the coffers of variowi nations both directly by productive 
employment and indirectly by improving llle health of the popl~lations. 
il If]. an industry where products face a forbidding rate of obsolescence, basic l'-' -
f 
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reSearch becomes essential for survival. Credited as we are with having one 
t., the largest technically trained man-power in the world on the one hand 
and on the other hand, having the second largest population with widespread 
incidence of tropical and other diseases, it becomes an interesting as well 
as important exercise to assesss what our conI ributions have been towards 
the development of new drugs. A primary requisite for such an appraisal 
is an understanding of tile process for drug development. 
i' l!!OCESSFOR NEW DRUG DEVELOPMENT: 
The design and development of new drugs call (or an array of costly and 
SophiSticated inputs. It is complex and long-drawn out and requires a multi-
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disciplinary team of chemists, biologists, toxicologists, biochemists and 
cians. The process begins with the identification of research progral 
and projects by drug development groups - industrial units, national lai 
tories, medical centres, etc. taking into account the medical needs of 
environment, marketing opportunities and inputs, financial considerat 
national and company policies and contemporary insights into disease proce. 
Action is then initiated in the chemical laboratory, where, after interae 
of chemists with biologists and based upon folk-lore medicines, biocherr. 
concepts or novel chemical ideas or insights, a new synthetic compounc 
a plant extract or a pure plant product is preapred. 
These substances are then screened by a team of biologists in a variety 
animal models or other test systems for diverse indications. The discov 
of a lead which occurs once in a while, despite its rarity, serves as an impe 
to intensifying all round efforts. This lead is then optimised by molecu 
modifications based upon intuition, semiempirical or quantitative structu 
activity relationships and computer-assisted molecular modelling of speculatl 
drug-receptor interactions. A candidate drug thus identified may be no, 
one for a disease indication for which prior therapy did not exist; or' I 
an indication for which treatment exists, it may promise an alternative appr 
ach with a different mode of action; or at the least, if it is, an analogi 
of an existing drug, it should show some quantitative and/or qualitative adva/ 
tages. 
From this point onwards, drug development follows a well-recognized courSE 
Detailed biological and sub-acute toxicity data as well as some inlormatio 
on the biotransformations of the candidate drug in animals are submitte( 
to the Drug Controller or equivalent regulatory authority for permission tc 
carry out Phase I or human tolerability studi€s, using a suitable formulation 
Abroad, the studies are frequently carried out in-house, while in India thej 
: 3 : 
must· be undertaken in public medical institutions through approved doctors. 
Acceptable tolerability allows the transtition to Phase II trials involving dose 
searching for efficacy. These two studies are usually restricted to a small 
number of centres. Along with tolerability and efficacy data, bioavailability 
a'nd human biotransformation information is also obtained in these studies. 
The clinical pharmacologists who are involved with these phases of drug deve-
lopment play a pivotal role, since their experience serves to give important 
feedback to the laboratory scientists concerning the suitability of the formula-
tion and efficacy in relation to dose and blood levels. Many a candidate drug 
becomes a casuality at this stage, ostensibly because animal data often cannot 
be extrapolated to Ilumans. Neverthless, the observant and perceptive clinical 
pharmacologist is in a position to suggest potentially useful mOdifications 
to the formulation of the trial drug or to its structure. It is quite possible 
and it has happened often that a drug would have failed in a given indication 
but clinical astuteness would have discovered a different therapeutic appli-
cation. 
Success in the dose-searching efficacy studies would lead the candidate drug 
being subjected to double blind trials at a few centres against an existing 
standard drug. 
The candidate drug poised to enter Phase lJl multicentric trials then undergoes 
chronic toxicity studies. Its effects on reproduction would also be investigated. 
Ideally details of human absorption, excretion, distribution and metabolism 
would have been also obtained by now. Very frequently - more so nowadays 
than earlier - mutagenicity and carcinogenicity studies would be initiated, 
this being mandatory for certain classes of drugs. In parenthesis, it may be 
noted that in most parts of the West, strict adherence tv Good Laboratory· 
Practice conditions for all sucll studies is a must. Based upon the above infor-
mation, permissinn tn carry out the multicentric trials in a large number 
... ~~., ..... ~. 
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of patients is obtained. Registration or marketing approval of the candidate 
drug is granted upon successful completion of these trials and acceptance 
of the total data by Drug Regulatory authorities. 
With increasingly stringent regula tions, the task of developing new drugs 
has become Herculean. Contemporary reports indicate that the introduction 
of a new chemical entity as a drug takes 10-12 years and costs about Rs.650 
million ($ 50 million). The odds are in the neighbourhood of 1 to 15000 for 
a' substance to become a useful drug, although Janssen pharmaceutica has 
been more successful (1/1000). The situation is further aggravated by the 
faster obsolescence of drugs as compared to other products of daily use. 
DRUG DEVELOPMENT: THE WORLD SCENARIO: 
Notwithstanding the forbiding dimensions of the problem unfolded above, 
interest and investment continue unabated, especially in the developed count-
ries, in discovering newer drugs offering improvements over existing ones 
and conquering diseases which have survived such onslaughts so far. The efforts 
have been rewarded with rich dividends primarily in the form of useful addi-
tions to our therapeutic armamentarium. Equally importantly, the pharma-
ceutical industry with an estimated annual turnover of $ 150 billion is contri-
buting substantially to ma terial prosperity. Finally and most importantly, these 
endeavours have very significantly resulted in an increase of several orders 
of magnitude of our basic knowledge, pushing its frontiers to daring distances. 
NEW DRUG DEVELOPMENT - THE INDIAN SCENE RESEARCH CENTRES 
AND AREAS OF INTEREST 
Although there had been sporadic efforts earlier, the establishment of the 
Central Drug Research Institute in Lucknow, after the country attained Inde-
pendence in 1947, ma'y be considered to be the first serious attempt to create 
the multidisciplinary" milielu with reasonable infrastructure needed for new 
drug development. The Indian Drugs and Pharmaceuticals Reserach Centre, 
a similar venture, appeared on the scene much later. 
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Regional Research Laboratories in Hyderabad and Jammu have also deployed 
some efforts in this area. In ,j(e Private sector, CIBA-GEIGY Research Centre 
founded in 1963, may be considered to be private industry's first serious 
and fully integrated venture. Sarabhai Research Centre in Baroda started 
somewhat earlier on a smaller scale is reported to have now abandoned its 
new drug development programme. Research centres of Hoechst and Boots 
in Bombay were started on a mere modest scale than CIBA-GEIG Y, but are 
expanding slowly and steadily. Of the three, Hoechst has a programme on 
antibiotic research as one of its activities, while SKF Research Centre at 
Bangalore has it as its exclusive concern. In addition to these, there are vari-
ous institutions in the country which are specialising in certain areas, with 
new drug· development as a small component of their activities, ego Foundation 
for Medical Research (leprosy), Indian Cancer Research Institute ( Cancer) 
and Institute for Research in Reproduction (fertility) all in Bombay and Valla-
bhai Patel Chest Institute (Respiratory disorders) and National Institute for 
Communicable Diseases (malaria, filaria, etc.) in Delhi. Finally it may be 
mentioned that institutions like The All India Institute of Medical Sciences, 
New Delhi, K EM and JJ Hospitals, Bombay and King George Medical Hospital 
in Lucknow participate in Tlew drug op-velopment processes with inputs during 
clinical trials as well as occasionally in earlier phases. 
Among these, the Central Drug Research Institute has been working in several 
areas ranging from cardio-vascular diseases to bacterial and paraSitic infec-
tions, handling both synthetic compounds and natural products while otller 
Research Centres have been confining themselves to fewer indication, each 
one of them having some engogement in aUeast one or two 'tN!pical' diseases 
- parasitic and bacterial infections. elBA-GEIGY have disengaged themselves 
from involvement with plants while H(.Jechst has increased its e:nphasis in 
this area. The latter centre and SKF have L'ornmitments in antibiotic research, 
an area with which the R &. D divisions of Hindustan ontibiotics at Pimpri 
and Indian Drugs and Pharmaceuticals at Rishikesh are also inwJived. 
RESULTS OF INDIAN EFFORTS: 
We are now poised to look at the fruits of the endeavours of these instituUons 
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over mainly the last 25 years. 
Drugs that have been approved by the Drug Controller of India are listed 
below along wiLl! their indications: 
Tromaril (Enfenamic acid) 
Sintamil (Nitroxazepine) 
Centbutindole 
CentbucridiTie 
Guggu lipid 
Centimizone 
Methaqualone 
Taomex (Nonaperone) 
Ancletol (amoscanate) 
Va rsyl (tina loline) 
Cibemid (satranidazole ) 
Hamycin 
Antiinflammatory 
Antidepressant 
Antipsychotic 
Local anaesthetic 
Antihyperlipidemic 
Antithyroid 
Hypnotic 
Antipsychotic 
Anthelmintic 
Nasal decongestant 
Antiprotoloal 
Antifungal 
Among the above, Tromaril, Sintami[ and lJamycin have been marketed for 
some years, with the first two selling for about Hs. 10 million each. Centi-
mizone is available to the public, while centbutindolp., centbucridine and guggu 
lipid have been just released to potential manufacturers. Methaqualone was 
synthesised in India, but the discover), of its therapeutic potential and further 
development took place abroad. The remaining four are unlikely to be marketed 
for reasons embracing marketing or medical aspects. 
As the second level should be noted the {ollowing preparations which are 
in early or advanced clinical trials. 
Centchroman 
Centpropazine 
Centperazine 
Centazoione 
antifertility, antitumor (likely 
to be approved soon) 
antidepressant 
anUfilarial 
tranquilizer 
CenUwC[llin 
Curcumin 
ForsKolin 
Rhodorubicin 
Chandonium 
A benzimidazole 
carbamate 
benzothiozole 
isothiocyana te 
antihypertensive 
antiinflammatory 
antiglaucoma, 
positive inotrope 
antitumour 
neuromuscular blocker 
anthelmintic 
antifilarial 
To this list may be added two vaccines, one for leprosy and another for ferti-
lity control. Although not new chemical entities, these vaccines are mentioned 
since they are products of biomedical research. 
A few compounds with significant and interesting biological properties, which 
have advanced to preclinical toxicology may also be noted. 
HL 707 
L 84 7667 
Buquiterine 
jrlmonicins 
antiamoebic 
antimalarial 
antiallergic, bronchospasmolytic 
antibiotic 
Mention of course must be made that atleast 12 other preparations were 
taken to the clinic, but these failed to develop into useful drugs. The list 
includes 5 antihypertensives, an antidepressant, a hypnotic, two hypoglycemics, 
an antitussive - analgesic, an anxiolytic and an anti-small pox agent. 
While numerically, the picture painted as above looks rosy, there is no room 
for complacency. It must be conceded that none of the aT?proved drugs repre-
sents a major break-through. They are not. world-class blockbusters such as 
Tagamet (cimetidine, antiulcer), Zantac (ranitidine, antiulcer), Naprosyn (napro-
xen, antiinflammatory) and Procardia (nifedipine, antihypertensive- antianginal) 
With 1986 sales in U.S. alone of $ 546, 480, 285 and 215 million respectively. 
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SOME RELECTIONS ON THE STATUS OF NEW DRUG DEVELOPMENT IN INDIA:i 
It is obvious from these figures that the achievements of the country are _.: 
not commensurate with its size or requirements. An attempt is now made 
to analyze the reasons and offer remedial suggestions. 
a. Investment in new drug development: 
Available figures indicate that the Indian investment in R&D in Pharma-
ceuticals is arOW1d Rs. 400 million, out of which probably Rs. 150 million 
goes into basic research. This is in stark contrast to what a much smaller 
country like Japan spends on Pharmaceutical R&D. Thus in 1985, the figure 
for Japan was Rs. 30,000 million, out of which 17% or roughly Rs. 5100 million 
was allocated for basic research. Giant corporations like CIBA -G EIG Y and 
SK F alone invest sums of the order of Rs. 4100 million in this field. The 
norms for investment in R&D in the developed countries is about 7-16% 
of their turnover (eg. Wellcome 13%, Warner-Lambert 16%, Japan 7-%) while 
ours is at a piddling 2% - and this is already twice the average of I.he Indian 
Chemical Industries' investment in R&D! ConSidering that new drug develop-
ment is cost intensive, our lackluster performance is understanbly inevitable. 
On. the other hand, it must be borne in mind that our Pharma turnover in 
1986-87 placed at Rs. 21,000 million (bulk drugs Rs. 4,600 million) is just 
about 1 % of the world sales. The pharmaceutical divisions of severalmulti-
nationals like CIBA-GEIGY have a turnover of around Rs. 50,000 million. 
Our figure does not even measure upto tiny U.K.'s performance at the same 
level in 1985. 
The situation is aggravated further by the fact that due to various factors, 
including restrictive price control policies of our government, the profitability 
of our drug industry is very low with many firms slowly sliding into sickness. 
The balance sheets of two leading pharmaceutical concerns exemplify the 
malady - post tax profit of Rs. 50-60 million, at about 3-4% of their turnover. 
The gravity of the problem becomes immediately apparent if we consider 
the cost of developing a new drug as Rs. 600 million : Astra Director, Peter 
Sjostrand's statement is particularly relevant to our situation - 'Minimum 
level of profit at which a company can be competitive in our opinion is 20% 
of total working capital - 20-25% is Q desirable profit level!' 
It remains to be seen whether the newly announced modified Drug Pricing 
Policy of the Indian Government would remedy the situation. The first impress-
ion is not very optimistic. 
The patent situation is also detrimental to significant investment in. research 
since' only processes and not products derive protection - and that too for 
a pitifully small period. 
b. Manpower, scientific milieu: 
Although India does have a vast pool of scientific/technical manpower, there 
is a dearth of people with the right kind of background in drug development, 
especially in biomedical sciences - biologists of various hues, biochemists, 
clinical pharmacologists, etc. the situation in Chemistry being slightly better. 
Even there', talent in synthetic chemistry abounds but weaknesses are apparent 
in expertise in applications or quantitative structure - activity relationships 
and computer-assisted molecular modelling both or which are integral to 
modem rational drug design. A consid~rable number of such people with the 
requisite training prerer to stay aborad. 
There are very few institutions in the country which offer formal training 
for this vocation; it is mostly an inhouse exercise within drug development 
groUps, although it must be mentioned that GS Medical College in Bombay 
uniquely offers a programml? in clinical pharmJcology ror new drug develop-
ment. 
In Contrast to the developed countries, the climate of vigorous, academic 
basic research in bio:nadical sciences that is a prelude to drug discoveries 
is lOcking in India; nor is the country located conveniently in the international 
circuit' of seminars and symposia which offer vicarious a wareness of the latest 
trends and avenues for cross fertilisation of ideas. The country has barely 
Woken up to the potentials of the explosive growth of ger:c::ic engineering 
Gnif'bio-teChnology. 
~, 
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Finally the cost of sophisticated tools indispensable to new drug development 
has become too prohibitive for the Indian Drug Industry, insult being added 
to injury by the Government in the form of import duty extending upto 140% .. 
The Universities and National Laboratories are fortunately not crippled by 
this duty. 
c. Areas or Research: 
The need for drug development efforts in India to concentrate on 'tropical 
diseases' is a familiar and understandable issue. However, one tends to easily 
forget or overLook the fact that cost-e/Iective drugs are already available 
to combat and control many parasiUc and bacterial infections - helminthiasis, 
amoebiasis, malaria, tuberculosis and leprosy. Considering that our drug 
prices are some of the lowest in the world, if they are still beyond the reach 
of the poorest segment of the population, a certain measure of government 
subsidy becomes inevitable to reach these drugs to the masses. Resfstant 
malaria and filaria still need adequate solutions - perhaps the vaccines in 
the horizon may be the answer to these challenges. Obviously, a more realistic 
solution to the problem lies in increased personal and community hygienic 
measures. Drugs to control fertility however do represent a crying need. 
On the other hand, there is no doubt that increasing sections of the Indian 
population are afflicted with the diseases of tile 'affluent'. efforts ill these 
areas are certainly not to be ignored or scoffed at. In fact they become nf!('e-
ssary and justifiable if we consider the obvious fact that our drug development 
efforts will be profitable only if they are aimed at and succeed in capturing 
a share of tile world market. The reality of a much smaller sales potential 
for tropical diseases cannot be wished away and, in fact, the only solution 
for the dilemma can be a heavy subsidy j'rom llle Government for research 
in these areas directly or indirectly through relaxation of pricing curbs. 
Finally in this section should be noted that new drug development in India 
should not only stick to new chemical entities by conventional synthesis, 
but also try to exploit our plant resources, validating by modern techniques, 
'some of the claims of Ayurveda, and other traditional systems of medicine. 
The emerging science of genetic engineering needs also to be harnessed for 
production of both vaccines as well as for the therapeutically active-
ooptides and smaller molecules. 
~ . . 
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::F? Conclusion: 
~/~~:;·,t,.e challenges of new drug development have assumed such formidable propor-
\'1:;;;:f,ons that we cannot hope to grapple with them with our tns{gnifi~ant resour-
.... ,ce". That these processes have become intemationalised are as much due 
":,:.... . 
: .s," to economic compulsions as to locational, logistic, tactical and strategic 
. reasons. Our national interests and goals in the area of drug development 
~o.Uld be best served by adherence toa global approach. Fears of multina-
;,', tionals using cheap labour in India or using Indians as guinea pigs have been 
'~~:~;.::: " ~'." .1" ::. • 
e~~:: frequently expressed. viz. the fulminations of Nature Correspondent against 
).~:.~:'.;:~"J~'~~;'~'-' . . 
_i~>~Jhe Astra Foundation in Bangalore or the news reports on the Indo- US Joint 
~~,L;}ci'c~ine' Action Programme. Considering that multinational ventures such 
:-.,::;" .. "."; 
?;a~ these serve both our short and long term interests and that adequate safe 
:'fl!J!l~ against exploitation can be and are built into them at the governmental 
.' . 1'.;.',";;' ~.. . 
level, diatribes appear to be political phoebias, or unjustified over-reactions, 
If we give 'the critics benefit of doubt. On the other hand, multinationals 
···.··.··.liJvestmg in basic drug research in India have to ensure that they do not 
,;:,::_,'~IP' _ ;./ -' _ 
.X:. J~(Jt their Indian Centres as poor relations with a symbolic status, that they 
i;~,:·:t,'·b":>'-·· . 
~-<:,~~" t~ated as equal partners in a joint and noble venture, that they are also 
.·.j,'~yc.>~ved in profitable projects of international dimensions and that their 
.... ,';..'< . ..;..;.,,'" 
products reach a fruitful international status. 
research is not itself a science, it is still an art or craft. 
WILUAM lIDo ClEORCR 
ors seem to have settled for what is measurable instead of measur-
-they would really like to know. 
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